This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Otsuka Holdings Co., Ltd.
Drug Names(s): Aripiprazole with Proteus ingestible sensor
Description: Abilify/Proteus is a combination product of Abilify (aripiprazole) embedded with a Proteus ingestible sensor in a single tablet. When ABILIFY with the embedded ingestible sensor is taken, the ingestible sensor sends a signal to the wearable Proteus patch after it reaches the stomach. The patch records and time-stamps the information from the ingestible sensor in addition to collecting other patient metrics, including rest, body angle and activity patterns. This information is recorded and relayed to patients on a mobile phone or other Bluetooth-enabled device, and with their consent, to their physician and/or their caregivers. Patients view the information using a secure and local software application on their mobile phone or device. Physicians and caregivers view the data using secure web portals.
Otsuka and Proteus
In July 2012, Proteus and Otsuka announced they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines. These new medicines will be based on Otsukas pharmaceutical products and Proteuss digital health feedback system incorporating Proteuss sensor-based technologies. Under the agreement, Proteus and Otsuka have entered an exclusive collaboration to develop commercial products in two defined therapeutic areas of high unmet medical need. Otsuka has also been granted a non-exclusive license to utilize Proteus technology in its clinical research and development activities. Financial terms of the agreement were not disclosed.
Partners: Proteus Digital Health, Inc.
Additional information available to subscribers only: